5HT2A polymorphism His452Tyr in a German Caucasian systemic sclerosis population

ar2606 ARJ Letter 5HT2A polymorphism His452Tyr in a German Caucasian systemic sclerosis population Kirsten Holger holger.kirsten@izi.fraunhofer.de Burkhardt Jana jana.burkhardt@medizin.uni-leipzig.de Hantmann Helene helene.hantmann@izi.fraunhofer.de Hunzelmann Nico nico.hunzelmann@uni-koeln.de Vaith Peter peter.vaith@uniklinik-freiburg.de Ahnert Peter peter.ahnert@izi.fraunhofer.de Melchers Inga Inga.melchers@uniklinik-freiburg.de

Institute of Clinical Immunology and Transfusion Medicine, Center for Biotechnology and Biomedicine (BBZ), University of Leipzig, Johannisallee, 04103 Leipzig, Germany

Fraunhofer Institute for Cell Therapy and Immunology, Perlickstr., 04103 Leipzig, Germany

Translational Center for Regenerative Medicine, University of Leipzig, Phillip-Rosenthal-Str., 04103 Leipzig, Germany

Department of Dermatology, University of Cologne, Kerpener Straße, 50924 Cologne, Germany

Department of Rheumatology and Clinical Immunology, University Medical Center Freiburg, Hugstetter Str., 79106 Freiburg, Germany

Institute for Medical Informatics, Statistics and Epidemiology, University of Leipzig, Haertelstr. 16-18, 04107 Leipzig, Germany

Clinical Research Unit for Rheumatology, University Medical Center, Breisacher Str., 79106 Freiburg, Germany

Arthritis Research & Therapy 1478-6354 2009 11 2 403 http://arthritis-research.com/content/11/2/403 See related research by Beretta et al., http://arthritis-research.com/content/10/5/R103 and related letter by Beretta and Scorza, http://arthritis-research.com/content/11/2/404 1943546510.1186/ar2606 26 3 2009 2009 BioMed Central Ltd

Recently, Beretta and colleagues 1 reported a protective association of the serotonin 5-HT_2Areceptor gene polymorphism His452Tyr (C+1354T, rs6314) with systemic sclerosis (SSc) in an Italian population. 5HT_2Aaccounts for most vasoconstrictive and platelet aggregation due to serotonin activity 2. Beretta and colleagues also demonstrated that plasma from healthy heterozygous carriers of His452Tyr showed decreased platelet aggregation after serotonin stimulus compared to plasma from healthy individuals homozygous for His452. In consequence, they suggested a functional role of His452Tyr in reducing susceptibility to SSc.

We performed a population-based replication study in an independent and larger German Caucasian SSc cohort, approved by local ethics committees. DNA was purified from blood samples after obtaining written informed consent. Patients were included according to the German Network for Systemic Scleroderma guidelines 3. The patient cohort was characterised as follows 4: all fulfilled minimal requirements of LeRoy and colleagues 5 and 81% fulfilled ACR criteria 6; 80% were females, 50% presented with the limited cutaneous form (lSSc 3), 33% with the diffuse cutaneous form (dSSc 3), 89% carried antinuclear antibodies (ANA-positive), 43% anticentromere antibodies (ACA-positive), 39% antitopoisomerase I antibodies (ATA-positive), and they had a mean age of disease onset of 49.5 ± 13.8 years. Mass spectrometry-based genotyping was applied as described, with minor modifications 4. Power was >96% to replicate the allelic association and >99% to replicate a decreased minor allele frequency within cases 7, as reported for the Italian population.

HapMap data reveal considerable variation of Tyr452 frequency among populations. It is especially high within Africans, emphasizing the importance of appropriate case-control matching. The frequency in our controls was very similar to that in the Caucasian HapMap cohort (0.065 versus 0.063, respectively). It was higher in the Italian population (0.124).

We did not find a protective association of His452Tyr with SSc. In contrast, the frequency of Tyr452 was not decreased, but even increased in all SSc patients (Table 1). Also, no association was found when SSc subgroups stratified for the fulfilment of ACR-criteria, clinical classification (lSSc, dSSc), autoantibody status (ANA-, ACA-, ATA-positive) or sex were compared to healthy donors. However, Tyr452-positive SSc patients were less frequently dSSc positive than His452 homozygous SSc patients (P = 0.048, 9% versus 20%, respectively). This might indicate that the 5HT_2Apolymorphism may influence the severity of SSc.

Table 1

Distribution of C+1354T within German systemic sclerosis patients and controls

Genotype

C versus T

Total

MAF

OR (95%CI)

P ^a

Patients

176

209

0.084

1.32 (0.8–2.2)

0.28

Controls

203

232

0.065

^aP-values were calculated with Fisher's exact test. Genotypes in cases and controls were consistent with Hardy-Weinberg equilibrium. Frequencies of genotypes were also not significantly different between patients and controls (P = 0.52, exact Fisher Freeman Halton test). CI, confidence interval; MAF, minor allele frequency; OR, odds ratio.

In summary, we could not replicate an association of the 5HT_2AHis452Tyr polymorphism with SSc in a larger German Caucasian cohort. However, an influence of this single nucleotide polymorphism on severity of SSc may exist.

Abbreviations

SSc: systemic sclerosis.

Competing interests

The authors declare that they have no competing interests.

Acknowledgements

Support originated from the BMBF ('German Network for Systemic Scleroderma' to IM and NH; 'Hochschul-Wissenschafts-Programm'to PA), the SAB (7692/1187) and EFRE (EFRE4212/04-04) to PA.

A polymorphism in the human serotonin 5-HT2A receptor gene may protect against systemic sclerosis by reducing platelet aggregation Beretta L Cossu M Marchini M Cappiello F Artoni A Motta G Scorza R Arthritis Res Ther 2008 10 R103 2592780 18761744 10.1186/ar2495 Proliferation and signaling in fibroblasts: role of 5-hydroxytryptamine2A receptor and transporter Welsh DJ Harnett M MacLean M Peacock AJ Am J Respir Crit Care Med 2004 170 252 259 10.1164/rccm.200302-264OC 15087293 The registry of the German Network for Systemic Scleroderma: frequency of disease subsets and patterns of organ involvement Hunzelmann N Genth E Krieg T Lehmacher W Melchers I Meurer M Moinzadeh P Müller-Ladner U Pfeiffer C Riemekasten G Schulze-Lohoff E Sunderkoetter C Weber M Worm M Klaus P Rubbert A Steinbrink K Grundt B Hein R Scharffetter-Kochanek K Hinrichs R Walker K Szeimies RM Karrer S Müller A Seitz C Schmidt E Lehmann P Foeldvári I Reichenberger F Rheumatology 2008 47 1185 1192 2468885 18515867 10.1093/rheumatology/ken179 No association between systemic sclerosis and C77G polymorphism in the human PTPRC (CD45) gene Kirsten H Blume M Emmrich F Hunzelmann N Mierau R Rzepka R Vaith P Witte T Melchers I Ahnert P J Rheumatol 2008 35 1817 1819 18634151 Scleroderma (systemic sclerosis): classification, subsets and pathogenesis LeRoy EC Black C Fleischmajer R Jablonska S Krieg T Medsger TA Jr Rowell N Wollheim F J Rheumatol 1988 15 202 205 3361530 Preliminary criteria for the classification of systemic sclerosis (scleroderma) Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee Arthritis Rheum 1980 23 581 590 10.1002/art.1780230510 7378088 IRF5 rs2004640-T allele, the new genetic factor for systemic lupus erythematosus, is not associated with rheumatoid arthritis Garnier S Dieude P Michou L Barbet S Tan A Lasbleiz S Bardin T Prum B Cornelis F Ann Rheum Dis 2007 66 828 831 10.1136/ard.2006.061390 17158136